Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Expanded Access Study of Trastuzumab Deruxtecan in HER2-Positive Advanced Gastric or GEJ Adenocarcinoma (Japan)
jRCT2080225138Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Mar 2020
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of trastuzumab deruxtecan in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Daiichi Sankyo Co., Ltd. Started Mar 2020; status: completed.
02
Drugs
trastuzumab deruxtecan
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on jRCT2080225138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225138.